These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11672951)

  • 21. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
    Pai RV; Jain RR; Bannalikar AS; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastroretentive delivery of rifampicin: in vitro mucoadhesion and in vivo gamma scintigraphy.
    Pund S; Joshi A; Vasu K; Nivsarkar M; Shishoo C
    Int J Pharm; 2011 Jun; 411(1-2):106-12. PubMed ID: 21458549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gelatin microspheres of rifampicin cross-linked with sucrose using thermal gelation method for the treatment of tuberculosis.
    Samad A; Sultana Y; Khar RK; Chuttani K; Mishra AK
    J Microencapsul; 2009 Feb; 26(1):83-9. PubMed ID: 18608799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I pharmacokinetic study of a new 3-azinomethyl-rifamycin (rifametane) as compared to rifampicin.
    Potkar C; Gogtay N; Gokhale P; Kshirsagar NA; Ajay S; Cooverji ND; Bruzzese T
    Chemotherapy; 1999; 45(3):147-53. PubMed ID: 10224335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.
    Garcia Contreras L; Sung J; Ibrahim M; Elbert K; Edwards D; Hickey A
    Mol Pharm; 2015 Aug; 12(8):2642-50. PubMed ID: 25942002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The WHO simplified study protocol in practice: investigation of combined formulations supplied by the WHO.
    Panchagnula R; Kaur KJ; Singh I; Kaul CL
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S336-42; discussion S351-2. PubMed ID: 10593714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.
    Stott KE; Singh B; Beadsworth MB; Vaudrey K; Khoo SH; Davies G
    Pharmacotherapy; 2016 Apr; 36(4):e23-5. PubMed ID: 26928044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
    Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
    Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin.
    Doan TV; Grégoire N; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC
    Eur J Pharm Sci; 2013 Jan; 48(1-2):223-30. PubMed ID: 23159665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo/in vitro pharmacokinetic and pharmacodynamic study of spray-dried poly-(dl-lactic-co-glycolic) acid nanoparticles encapsulating rifampicin and isoniazid.
    Booysen LL; Kalombo L; Brooks E; Hansen R; Gilliland J; Gruppo V; Lungenhofer P; Semete-Makokotlela B; Swai HS; Kotze AF; Lenaerts A; du Plessis LH
    Int J Pharm; 2013 Feb; 444(1-2):10-7. PubMed ID: 23357255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solubility and dissolution properties of generic rifampicin raw materials.
    Henwood SQ; de Villiers MM; Liebenberg W; Lötter AP
    Drug Dev Ind Pharm; 2000 Apr; 26(4):403-8. PubMed ID: 10769781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A fiber optic chemical sensor system for on-line monitoring the drug dissolution of rifampicin].
    Li XX; Wang YW; Wang Y; Chen J
    Yao Xue Xue Bao; 2002 Sep; 37(9):721-3. PubMed ID: 12567899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation and in vitro characterization of inhalable rifampicin-loaded PLGA microspheres for sustained lung delivery.
    Doan TV; Couet W; Olivier JC
    Int J Pharm; 2011 Jul; 414(1-2):112-7. PubMed ID: 21596123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biphasic drug release: permeability and swelling of pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs.
    Fan LF; He W; Bai M; Du Q; Xiang B; Chang YZ; Cao DY
    Chem Pharm Bull (Tokyo); 2008 Aug; 56(8):1118-25. PubMed ID: 18670112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
    Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
    Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
    Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market.
    Singh S; Mariappan TT; Bhutani H
    Int J Tuberc Lung Dis; 2005 Jun; 9(6):701-2. PubMed ID: 15971403
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin.
    Makino K; Nakajima T; Shikamura M; Ito F; Ando S; Kochi C; Inagawa H; Soma G; Terada H
    Colloids Surf B Biointerfaces; 2004 Jul; 36(1):35-42. PubMed ID: 15261021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical study of suppository formulations for improved in vivo kinetics of rifampicin.
    Taki H; Ogawa K; Nikai T
    Kekkaku; 2008 Jun; 83(6):451-6. PubMed ID: 18634449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.